Therefore, SFRP2 promotes an osteoblastic phenotype in early metastasized prostate cancer cells and therewith promotes cell survival, or it additionally induces osteoblastic bone lesion in later stages due to an increase in osteoblastic differentiation. This evidence concerns the gene SFRP2 and prostate cancer.